<DOC>
	<DOCNO>NCT00554203</DOCNO>
	<brief_summary>Experimental study suggest systemic inflammation lead endothelial dysfunction atherosclerosis . This study examine effect anti-inflammatory drug sulfasalazine endothelial function patient coronary artery disease . Subjects treat sulfasalazine placebo six week . After two-week rest period , subject cross alternative treatment . Endothelium-dependent flow-mediated dilation brachial artery study drug . We hypothesize anti-inflammatory therapy reverse endothelial dysfunction patient coronary artery disease .</brief_summary>
	<brief_title>Sulfasalazine Endothelial Function</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>History coronary artery disease G6PD deficiency define red blood cell G6PD activity assay Sulfa allergy Aspirin allergy Allergy furosemide ( lasix ) , hydrochlorthiazide , sulfonylurea , acetazolamide ( Diamox ) carbonic anhydrase inhibitor SGOT , SGPT , alkaline phosphatase , total bilirubin great 2 time upper limit normal WBC le 4.0 great 11.0 K/UL Platelet count le 150 K great 450K Hematocrit less 30 % 7 Serum creatinine great 1.5 mg/dl Unstable angina acute MI within 2 week Warfarin treatment Immunosuppressive treatment ( methotrexate , cyclosporine , etc . ) Digoxin treatment Phenytoin ( Dilantin ) treatment Methenamine ( Mandelamine , Urex ) treatment Probenecid sulfinpyrazone ( Anturane , Aprazone ) treatment Porphyria Symptomatic GI obstruction GU obstruction ( include clinical evidence benign prostatic hypertrophy ) Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
</DOC>